Aromatase Inhibitors: Complete Guide for Men on Cycle

Aromatase inhibitors are drugs that block aromatase, the CYP19A1 enzyme that converts androgens into estrogens. Three are in clinical use: exemestane (Aromasin), anastrozole (Arimidex) and letrozole (Femara), all approved for hormone receptor-positive breast cancer in postmenopausal women, where cutting estrogen production starves the tumour. In men they are used off-label for one purpose: keeping estradiol in a functional range when testosterone is high enough that conversion runs away.

In a man, aromatase produces the majority of circulating estradiol from testosterone and androstenedione, and it lives mostly in body fat. At normal testosterone the conversion is modest and useful: estradiol supports bone, libido, mood, lipids and joints. On 500 mg of testosterone per week the substrate is five to ten times normal and estradiol climbs with it, bringing water retention, blood pressure, nipple sensitivity and mood swings. An aromatase inhibitor interrupts that conversion, and the entire skill of using one is holding estradiol at 20–40 pg/mL rather than driving it to zero.

This guide is the hub for the topic. It covers the two mechanistic classes, the three drugs, dosing by testosterone dose, PCT, side effects and blood work, and links to the detailed article on each.

Not all aromatase inhibitors work the same way, and the difference in binding drives every practical difference in dosing, recovery and PCT use.

Type I, steroidal, irreversible: exemestane is shaped like the enzyme's natural androgen substrate, so aromatase processes it and is permanently inactivated in doing so. The body has to synthesise new enzyme, which takes days. That is why exemestane is dosed every other day, why estradiol recovers gradually over three to seven days after stopping, and why it does not interfere with the SERM-driven LH and FSH response in PCT. The Aromasin half-life guide explains why its 24-hour half-life and four-to-five-day effect diverge. The clinical side of that mechanism is explained in exemestane drug class.

Type II, non-steroidal, reversible: anastrozole and letrozole occupy the enzyme's binding site competitively and release it as the drug clears. Their effect depends on sustained plasma levels, which is why they carry long half-lives, around 50 hours for anastrozole and two to four days for letrozole. Recovery after stopping is fast, one to two days for anastrozole, with a rebound risk when inhibition lifts suddenly, and both blunt the gonadotropin response a SERM relies on.

Aromasin (exemestane) is the most widely used and the default for most protocols. 12.5 mg EOD for 400–600 mg of testosterone per week, 25 mg EOD at 750 mg and above, in scored 25 mg tablets. Its advantages are PCT compatibility, fewer joint complaints than anastrozole at the same estradiol, and a gradual offset that makes an overshoot easier to catch. Its limitation is coarse dosing: 12.5 or 25 mg with nothing clean between. The Aromasin bodybuilding guide covers its use from cycle start to PCT.

Arimidex (anastrozole) is the alternative with fine titration. 0.5 mg EOD standard, quartered to 0.25 mg where precision matters at low testosterone doses, with estradiol responding to a dose change within one to two days. Its limitations are PCT incompatibility, more joint pain at comparable estradiol, and rebound on stopping. The Aromasin vs Arimidex comparison sets the two side by side with the MA.27 trial data.

Letrozole (Femara) is the most potent. At its clinical 2.5 mg daily it takes estrogen to near-undetectable levels; at bodybuilding doses of 0.5–1 mg EOD it still crashes moderate aromatisers quickly. It is a tool for reversing established gynecomastia under supervision or for very high testosterone doses where exemestane at 25 mg EOD has failed, and not a first-line cycle AI.

The dosing framework has one fixed element, blood work at week four or five on a sensitive estradiol assay with a 20–40 pg/mL target, and four variables: testosterone dose, body fat, genetics and which drug.

Body fat above roughly 18–20% moves a man up a row. A previous cycle where the starting dose left estradiol above 50 pg/mL at the same testosterone dose does the same. The Aromasin dosage guide covers the 12.5 versus 25 mg decision, tablet splitting, timing against injections and TRT dosing, and the 500 mg test cycle protocol works through the most common row week by week.

Post-cycle therapy depends on a SERM, tamoxifen or clomiphene, blocking estrogen receptors at the pituitary and hypothalamus so that negative feedback lifts and LH and FSH rise. For that to work, the gonadotropin response to GnRH has to be intact.

Anastrozole and letrozole have been shown to suppress the FSH and LH response to GnRH, blunting the exact signal the SERM is generating. Exemestane's steroidal mechanism carries no such effect, which makes it the only pharmaceutical AI compatible with a SERM-based PCT. An AI is still needed in the first weeks because, as exogenous testosterone clears, estradiol stays high relative to the falling androgen level and suppresses recovery.

Practical protocol: whatever ran on cycle, switch to exemestane 12.5 mg EOD for the first two to three weeks of the SERM phase, allowing anastrozole two to three days to clear first, then taper to every third day and stop by week four. The cycle hub sets the PCT phase in the wider cycle plan.

The side effects attributed to these drugs in men are overwhelmingly the result of estradiol suppressed too far, not drug toxicity, and the fix is a lower dose rather than a different drug or a supplement.

Over-suppression, below roughly 15–20 pg/mL: dry, aching joints, libido loss despite high testosterone, low mood and flat affect, fatigue, flat pumps, brain fog. All of it resolves as estradiol recovers.

Compound-specific: anastrozole produces more joint pain than exemestane at the same estradiol, possibly through an effect on collagen beyond aromatase inhibition, and men who switch usually improve. Exemestane can nudge liver enzymes when stacked with an oral.

Long-term: bone density loss accumulates over years of AI use, and every AI lowers HDL. The MA.27 trial in 7,576 women found less osteoporosis and better lipids on exemestane than anastrozole, which is why it is preferred for anything extended. Minimum effective dose, calcium, vitamin D and weight training are the protection. The aromatase inhibitors side effects guide covers each in depth, including how to tell a crash from a compound effect.

Every section of this guide comes back to one practice.

The how to lower estrogen in men guide sets out the male reference ranges and what each band means.

Not every man on testosterone needs one. Most men on TRT at 100–200 mg per week hold estradiol in range without an AI, and adding one reflexively produces the crashed-estrogen picture that gets blamed on the testosterone. Men on non-aromatising compounds alone, trenbolone, stanozolol or oxandrolone, have no estrogen to control. Men on a cycle who have not yet drawn blood do not yet know.

The clear indications are a cycle of aromatising compounds with a sensitive estradiol above 50 pg/mL and symptoms; TRT with the same result after injection frequency and body fat have been addressed; and, under a physician, naturally high estradiol that lifestyle change has not fixed. The aromatase inhibitors for men guide covers the decision, including the off-label clinical use of anastrozole to raise testosterone in men with hypogonadism.

What does not qualify for cycle purposes is anything sold over the counter. DIM-based "estrogen blockers" alter estrogen metabolism without touching the enzyme; arimistane gave weak real inhibition but is no longer a legal supplement ingredient. The natural aromatase inhibitors guide ranks the compounds by human evidence and the arimistane review covers the OTC option in detail; the best estrogen blocker for men guide compares prescription and OTC by situation. Mesterolone (Proviron) is often listed alongside aromatase inhibitors but is a weak one at best; its real role is SHBG binding, explained in what is Proviron.

Aromasin.org is an independent educational resource. We are not affiliated with Pfizer, any pharmaceutical manufacturer, or healthcare provider. This content is for informational purposes only and does not constitute medical advice.